Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.63 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.48 |
| ▸ | CPT1A | P50416 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282734 | 0.87 | ABHD6 (0.61) | ABHD6RIPK1AKR1C3CPT2CPT1A | |
| SCHEMBL7007674 | 0.85 | ABHD6 (0.64) | ABHD6AKR1C3CPT2CPT1ANOTUM | |
| SCHEMBL1136171 | 0.82 | RIPK1 (0.58) | ABHD6RIPK1AKR1C3NOTUMHDAC6 | |
| SCHEMBL3167899 | 0.81 | RIPK1 (0.57) | ABHD6RIPK1AKR1C3NOTUMHDAC6 | |
| SCHEMBL20873627 | 0.81 | ABHD6 (0.63) | ABHD6RIPK1AKR1C3CPT2CPT1A | |
| SCHEMBL23817958 | 0.80 | ABHD6 (0.59) | ABHD6 | |
| SCHEMBL506664 | 0.78 | ABHD6 (0.63) | ABHD6AKR1C3NOTUMHDAC6HDAC1 | |
| SCHEMBL20983833 | 0.78 | ABHD6 (1.00) | ABHD6 | |
| SCHEMBL2794349 | 0.76 | RIPK1 (0.82) | RIPK1NOTUMHDAC6HDAC8 | |
| SCHEMBL23774171 | 0.76 | ABHD6 (0.50) | ABHD6AKR1C3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | ABHD6 3647/4885RIPK1 957/4885AKR1C3 3156/4885 |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ABHD6 3647/4885RIPK1 957/4885AKR1C3 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.